Anfield Capital Management’s Edwards Lifesciences EW Stock Holding History

Anfield Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$480	Hold	6	–	–	﹤0.01%	666
2025 Q4	$512	Hold	6	–	–	﹤0.01%	542
2025 Q3	$467	Buy	+6	New	+$469	﹤0.01%	560
2024 Q2	–	Sell	-51	Closed	-$4.87K	–	445
2024 Q1	$4.87K	Buy	+51	New	+$4.28K	﹤0.01%	208
2021 Q4	–	Sell	-105	Closed	-$12K	–	110
2021 Q3	$12K	Buy	+105	New	+$12K	﹤0.01%	90
2020 Q1	–	Sell	-3,204	Closed	-$247K	–	194
2019 Q4	$247K	Buy	+3,204	New	+$250K	0.1%	107

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Anfield Capital Management's EW Position: Q1 2026 in Review

Anfield Capital Management held its Edwards Lifesciences (EW) position steady in Q1 2026 at 6 shares worth $480. The position accounts for ﹤0.01% of the portfolio, ranked #666.

Anfield Capital Management first reported a position in EW in Q4 2019 and has held it in 6 quarters since. The position peaked at $247K in Q4 2019. 1,288 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Anfield Capital Management held 6 shares of Edwards Lifesciences worth $480 as of Q1 2026.
Anfield Capital Management left its Edwards Lifesciences share count unchanged in Q1 2026.
Edwards Lifesciences made up ﹤0.01% of Anfield Capital Management's portfolio in Q1 2026, its #666 holding.
Anfield Capital Management first reported a position in Edwards Lifesciences in Q4 2019 and has held it in 6 quarters since.
Anfield Capital Management's Edwards Lifesciences position peaked at $247K in Q4 2019.
1,288 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.